Europe omega-3 ingredients for pharmaceuticals market are projected to register a healthy CAGR of 10.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Europe Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA)), Forms (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer, Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Sweden, Denmark, Poland, Turkey and Rest of Europe) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of Europe omega-3 ingredients for pharmaceuticals market are:
- Rising demand of functional and supplement food
- Rising burden of lifestyle diseases across globe leads the demand of omega-3 based products
Market Players:
The key market players for Europe omega-3 ingredients for pharmaceuticals market are listed below:
- Novasep
- AbbVie Inc.
- KD Pharma Group
- BASF SE
- Corbion NV
- DSM
- AstraZeneca
- GlaxoSmithKline plc
- Croda International Plc
- AMARIN CORPORATION
- ANI Pharmaceuticals, Inc.
- Epax (a subsidiary of Pelagia AS)
- Strides Pharma Science Limited
- Pharma Marine AS
- Solutex
